Tech Company M&A Transactions
Shape Pharmaceuticals Acquisition
Headquartered in Cambridge, Shape Pharmaceuticals was acquired by TetraLogic Pharmaceuticals. The acquisition price was $13 million.
Transaction Overview
Company Name
Acquired By
Announced On
4/8/2014
Transaction Type
M&A
Amount
$13,000,000
M&A Terms
TetraLogic will make a $13 million up-front cash payment for Shape, followed by undisclosed potential development and commercialization milestones, as well as tiered royalties on product sales.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 301
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Shape Pharmaceuticals, Inc. is developing a novel, topical HDAC inhibitor, SHP-141, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Onsi
Founder
James Bradner
Founder
Ralph Mazitschek
Browse more venture capital transactions:
Prev: 4/7/2014: Daktari Diagnostics venture capital transaction
Next: 4/8/2014: Natero venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs